APRE - Rasio rega marang prakiraan pendapatan Aprea Therapeutics Inc.

Aprea Therapeutics (APRE) develops ATR inhibitors that increase tumor sensitivity to chemotherapy by disrupting cell division. The expected P/S ratio reflects market expectations, with 621.00 representing the latest metric reading. These developments are based on identifying vulnerabilities in DNA repair. The company is currently in the R&D stage, creating tools to combat cancer cell resistance.

Aprea - Prakiraan rega marang pendapatan APRE (periode 20.08.2023 - 05.11.2026)

Rincian metrik komprehensif lan analitis aprea.com (APRE)

- rega pasar lan target rega analis:

Bagan rega Aprea Therapeutics, Inc.|APRE - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar Aprea Therapeutics|APRE - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Aprea Therapeutics|APRE - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih aprea.com|APRE - Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Aprea Therapeutics|APRE - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Aprea Therapeutics, Inc.|APRE - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Aprea Therapeutics|APRE - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Aprea Therapeutics|Likuiditas cepet aprea.com

- rincian asil keuangan lan kelipatan valuasi:

APRE - Bathi pungkasan|Proyeksi bathi mangsa ngarep Aprea Therapeutics|APRE - Pangali P/E|Rega marang bathi mangsa ngarep Aprea Therapeutics, Inc.|APRE - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Aprea Therapeutics|APRE - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Aprea Therapeutics|APRE - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan aprea.com|APRE - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Aprea Therapeutics

- data pendapatan lan penerimaan dodolan:

APRE - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Aprea Therapeutics, Inc.|APRE - Rega marang dodolan|Multiplikator Forward P/S Aprea Therapeutics

Analisis umum perusahaan:Aprea APRE

Produk sing diprodhuksi Aprea Therapeutics Inc.

For Aprea Therapeutics (APRE), which holds exclusive patents for Eprenetapopt, the forward P/S ratio serves as a filter for market noise, benchmarking current market capitalization against projected revenue under strict FDA oversight. By analyzing the forward P/S dynamics of Aprea Therapeutics (APRE), an investor can assess whether market expectations regarding future sales are justified, enabling the identification of asset overvaluation or hidden growth potential before actual losses are realized.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte INCY|Hutchison MediPharma - Rasio rega marang prakiraan pendapatan|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One Biopharmaceuticals Inc|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan inhibrx.com INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharma FENC|Multiplikator forward rega marang pendapatan HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (corbuspharma.com)|Cardiff Oncology Corp - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring, Inc.)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Lixte Biotechnology, Inc. (LIXT)|Rasio rega marang prakiraan pendapatan Citius Pharmaceuticals Inc.|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S BLRX|Multiplikator Forward P/S Can-Fite BioPharma Ltd (CANF)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep chimerix.com|CYCC: Multiplikator Forward P/S|G1 Therapeutics (GTHX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Kronos Bio Corp|Kintara Pharma - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Oncternal Therapeutics (ONCT)|PRTG (portagebiotech.com) - Rega forward marang dodolan